Skip to main content
Erschienen in: Endocrine Pathology 2/2010

01.06.2010

RAS Mutation-Positive Follicular Variant of Papillary Thyroid Carcinoma Arising in a Struma Ovarii

verfasst von: Christopher Coyne, Yuri E. Nikiforov

Erschienen in: Endocrine Pathology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Struma ovarii is an ovarian mature teratoma composed exclusively or predominantly of thyroid tissue. Malignant transformation of struma ovarii is rare and poorly understood, although this process is thought to be similar to carcinogenesis in malignant tumors of differentiated thyroid tissue originating in the thyroid gland. Genetic alterations in the mitogen-activated protein kinase pathway, including mutations of BRAF, RAS, and RET genes, have been implicated in the development of differentiated thyroid carcinoma arising in the thyroid gland. We report here a case with RAS mutation detected in a malignant struma ovarii. The patient is a 38-year-old female who had a 2.4 cm ovarian cyst noted incidentally on a first trimester ultrasound. She proceeded to ovarian cystectomy post-delivery, with pathologic examination detecting a papillary thyroid carcinoma, follicular variant, arising in a cystic teratoma. The tumor was tested for BRAF, RAS, and RET/PTC mutations. HRAS codon 61 mutation was identified. This is the first report of RAS mutation detected in the follicular variant of papillary carcinoma arising in a struma ovarii. It provides evidence that tumors developing in this setting involve molecular mechanisms similar to those implicated in tumors developing in the thyroid gland.
Literatur
1.
Zurück zum Zitat Makani S, Kim W, Gaba A. Struma ovarii with a focus of papillary thyroid cancer: a case report and review of the literature. Gynecol Oncol 94:835–9, 2004.CrossRefPubMed Makani S, Kim W, Gaba A. Struma ovarii with a focus of papillary thyroid cancer: a case report and review of the literature. Gynecol Oncol 94:835–9, 2004.CrossRefPubMed
2.
Zurück zum Zitat Logani S et al. Cystic ovarian metastasis from papillary thyroid carcinoma: a case report. Thyroid 11(11):1073–5, 2001.CrossRefPubMed Logani S et al. Cystic ovarian metastasis from papillary thyroid carcinoma: a case report. Thyroid 11(11):1073–5, 2001.CrossRefPubMed
3.
Zurück zum Zitat Young R, Jackson A, Wells, M. Ovarian metastasis from thyroid carcinoma 12 years after partial thyroidectomy mimicking struma ovarii: report of a case. Int J Gynecol Pathol 13(2):181–5, 1994.PubMedCrossRef Young R, Jackson A, Wells, M. Ovarian metastasis from thyroid carcinoma 12 years after partial thyroidectomy mimicking struma ovarii: report of a case. Int J Gynecol Pathol 13(2):181–5, 1994.PubMedCrossRef
4.
Zurück zum Zitat Flavin R et al. BRAF T1799A Mutation occurring in a case of malignant struma ovarii. Int J Surg Pathol 15(2):116–20, 2007.CrossRefPubMed Flavin R et al. BRAF T1799A Mutation occurring in a case of malignant struma ovarii. Int J Surg Pathol 15(2):116–20, 2007.CrossRefPubMed
5.
Zurück zum Zitat Kimura ET et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–7, 2003.PubMed Kimura ET et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–7, 2003.PubMed
6.
Zurück zum Zitat Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–7, 2003.PubMed Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–7, 2003.PubMed
7.
Zurück zum Zitat Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578–80, 2003.CrossRefPubMed Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578–80, 2003.CrossRefPubMed
8.
Zurück zum Zitat Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 23(44):7436–40, 2004.CrossRefPubMed Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 23(44):7436–40, 2004.CrossRefPubMed
9.
Zurück zum Zitat Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625–7, 2003.PubMed Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625–7, 2003.PubMed
10.
Zurück zum Zitat Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–63, 1990.CrossRefPubMed Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557–63, 1990.CrossRefPubMed
11.
Zurück zum Zitat Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G, Pierotti MA. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54:2979–85, 1994.PubMed Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G, Pierotti MA. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54:2979–85, 1994.PubMed
12.
Zurück zum Zitat Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G, Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the retproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509–16, 1994.PubMed Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G, Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the retproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509–16, 1994.PubMed
13.
14.
Zurück zum Zitat Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474–9, 1990.CrossRefPubMed Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474–9, 1990.CrossRefPubMed
15.
Zurück zum Zitat Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6:409–16, 1996.CrossRefPubMed Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6:409–16, 1996.CrossRefPubMed
16.
Zurück zum Zitat Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71–7, 2003.CrossRefPubMed Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71–7, 2003.CrossRefPubMed
17.
Zurück zum Zitat Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216–22, 2006.CrossRefPubMed Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216–22, 2006.CrossRefPubMed
18.
Zurück zum Zitat Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Path 21:537–43, 2008.CrossRef Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Path 21:537–43, 2008.CrossRef
19.
Zurück zum Zitat Golbert L. H-RAS gene expression in human multinodular goiter. Histol Histopathol 22:409–16, 2007.PubMed Golbert L. H-RAS gene expression in human multinodular goiter. Histol Histopathol 22:409–16, 2007.PubMed
20.
21.
Zurück zum Zitat Cyniak-Magierska A et al. Prevalence of RAS point mutations in papillary thyroid carcinoma: a novel mutation at codon 31 of K-RAS. Exp Clin Endocrinol Diabetes 115:594–9, 2007.CrossRefPubMed Cyniak-Magierska A et al. Prevalence of RAS point mutations in papillary thyroid carcinoma: a novel mutation at codon 31 of K-RAS. Exp Clin Endocrinol Diabetes 115:594–9, 2007.CrossRefPubMed
22.
Zurück zum Zitat Hara H et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 116(6):1010–6, 1994.PubMed Hara H et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 116(6):1010–6, 1994.PubMed
24.
Zurück zum Zitat Cicarelli A et al. Thyrotoxic adenoma followed by atypical hyperthyroidism due to struma ovarii: clinical and genetic studies. Eur J Endocrinol 150:431–7, 2004.CrossRef Cicarelli A et al. Thyrotoxic adenoma followed by atypical hyperthyroidism due to struma ovarii: clinical and genetic studies. Eur J Endocrinol 150:431–7, 2004.CrossRef
25.
Zurück zum Zitat Suarez, HG. Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol 48:531–46, 1998.CrossRef Suarez, HG. Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol 48:531–46, 1998.CrossRef
Metadaten
Titel
RAS Mutation-Positive Follicular Variant of Papillary Thyroid Carcinoma Arising in a Struma Ovarii
verfasst von
Christopher Coyne
Yuri E. Nikiforov
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 2/2010
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-009-9097-8

Weitere Artikel der Ausgabe 2/2010

Endocrine Pathology 2/2010 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …